> Table 49: Combined modality treatment and overall survival in inflammatory breast cancer
This summary table contains detailed information about research studies. Summary tables offer an informative look at the science behind many breast cancer guidelines and recommendations. However, they should be viewed with some caution. In order to read and interpret research tables successfully, it is important to understand some key concepts. Learn how to read a research table.
|
Introduction: Inflammatory breast cancer is a rare, but aggressive form of breast cancer. It is treated with a combination of surgery, radiation and chemotherapy, and may include hormone therapy and/or targeted therapy. Because multiple therapies are used, this is often called combined modality treatment.
With combined modality treatment, five-year overall survival rates for inflammatory breast cancer range from about 30 to 70 percent (see studies below).
Study selection criteria: Clinical trials with 50 or more participants on combined modality treatment with at least five years follow-up.
Study
|
Study Population (number of participants)
|
Treatments Studied
|
5-year Overall Survival Rate
|
Clinical trials
|
Palangie et al. [1]
|
223
|
Chemotherapy>>radiation therapy>>chemotherapy with or without immunotherapy with or without hormone therapy with or without mastectomy
|
41%
|
Ueno et al. [2]
|
178
|
Chemotherapy>>radiation therapy>>chemotherapy
OR
Chemotherapy>>mastectomy>>chemotherapy>>radiation therapy
|
40%
|
Chevallier et al. [3]
|
178
|
Chemotherapy>>radiation therapy with or without mastectomy with or without chemotherapy
|
32%
|
Attia-Sobol et al. [4]
|
103
|
Chemotherapy>>radiation therapy>>chemotherapy
OR
Chemotherapy with or without radiation therapy with or without surgery with or without radiation therapy>>chemotherapy
|
55%
|
Untch et al. [5]
|
91
|
Dose-dense or standard chemotherapy>>lumpectomy>>chemotherapy>>radiation therapy
OR
Dose-dense or standard chemotherapy>>mastectomy with or without radiation therapy>>chemotherapy
|
65%*
|
Perez et al. [6]
|
86
|
Radiation therapy>>mastectomy>>chemotherapy
|
38%*†
|
Harris et al. [7]
|
54
|
Chemotherapy>>radiation therapy with or without mastectomy>>chemotherapy
OR
Chemotherapy>>mastectomy>>radiation therapy>>chemotherapy
OR
Mastectomy>>chemotherapy>>radiation therapy>>chemotherapy
|
56%
|
* Estimate from figure in article
† Breast cancer survival rather than overall survival
References
1. Palangie T, Mosseri V, Mihura J, et al. Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer. 7:921-7, 1994.
2. Ueno NT, Buzdar AU, Singletary SE, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol. 40:321-9, 1997.
3. Chevallier B, Bastit P, Graic Y, et al. The Centre H. Becquerel studies in inflammatory non-metastatic breast cancer. Combined modality approach in 178 patients. Br J Cancer. 67:594-601, 1993.
4. Attia-Sobol JA, Ferriere J, Cure H, et al. Treatment results, survival and prognostic factors in 109 inflammatory breast cancers: univariate and multivariate analysis. Eur J Cancer. 29A:1081-1088, 1993.
5. Untch M, Möbus V, Kuhn W, et al. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol. 27(18):2938-45, 2009.
6. Perez CA, Fields JN, Fracasso PM, et al. Management of locally advanced carcinoma of the breast. II. Inflammatory Carcinoma. Cancer. 74:466-76, 1994.
7. Harris EER, Schultz D, Bertsch H, et al. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J. Radiation Oncology Biol Phys. 55:1200-1208, 2003.
Updated 01/22/13
